Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations
Pseudoxanthoma elasticum (PXE) is an inherited systemic disease of connective tissue primarily affecting the skin, retina, and cardiovascular system. It is characterised pathologically by elastic fibre mineralisation and fragmentation (so called “elastorrhexia”), and clinically by high heterogeneity...
Saved in:
Published in | Journal of Medical Genetics Vol. 42; no. 12; pp. 881 - 892 |
---|---|
Main Authors | , , , , |
Format | Journal Article Book Review |
Language | English |
Published |
London
BMJ Publishing Group Ltd
01.12.2005
BMJ BMJ Publishing Group LTD BMJ Publishing Group BMJ Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pseudoxanthoma elasticum (PXE) is an inherited systemic disease of connective tissue primarily affecting the skin, retina, and cardiovascular system. It is characterised pathologically by elastic fibre mineralisation and fragmentation (so called “elastorrhexia”), and clinically by high heterogeneity in age of onset and the extent and severity of organ system involvement. PXE was recently associated with mutations in the ABCC6 (ATP binding cassette subtype C number 6) gene. At least one ABCC6 mutation is found in about 80% of patients. These mutations are identifiable in most of the 31 ABCC6 exons and consist of missense, nonsense, frameshift mutations, or large deletions. No correlation between the nature or location of the mutations and phenotype severity has yet been established. Recent findings support exclusive recessive inheritance. The proposed prevalence of PXE is 1/25 000, but this is probably an underestimate. ABCC6 encodes the protein ABCC6 (also known as MRP6), a member of the large ATP dependent transmembrane transporter family that is expressed predominantly in the liver and kidneys, and only to a lesser extent in tissues affected by PXE. The physiological substrates of ABCC6 remain to be determined, but the current hypothesis is that PXE should be considered to be a metabolic disease with undetermined circulating molecules interacting with the synthesis, turnover, or maintenance of elastic fibres. |
---|---|
Bibliography: | ark:/67375/NVC-XRMFN036-B istex:2B8E8CB856520C15AF7A9EF718BC3B128CD7EB95 local:0420881 href:jmedgenet-42-881.pdf PMID:15894595 Correspondence to: Dr Alain Hovnanian Department of Medical Genetics and INSERM U563, Pavillon Lefebvre, Purpan Hospital, Place du Dr Baylac, 31059 Toulouse Cedex 09, FRANCE; Email: alain.hovnanian@toulouse.inserm.fr ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-3 ObjectType-Review-1 PMCID: PMC1735972 |
ISSN: | 0022-2593 1468-6244 1468-6244 |
DOI: | 10.1136/jmg.2004.030171 |